Stock VNDA VANDA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 06/12/2024 GMT 		5-day change 1st Jan Change
4.840 USD +1.26% Intraday chart for Vanda Pharmaceuticals Inc. -6.02% +14.69%
11-06 Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q3 Revenue $47.7M MT
11-06 Vanda Pharmaceuticals Inc., Q3 2024 Earnings Call, Nov 06, 2024

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q3 Revenue $47.7M
11-06
 MT
Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024
11-06
 CI
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
11-06
 CI
HC Wainwright Starts Vanda Pharmaceuticals With Buy Rating, $18 Price Target
10-31
 MT
Global markets live: InPost, Nvidia, Coty, Verizon, Apple...
10-15
Our Logo
Sector Update: Health Care Stocks Rise Late Afternoon
10-14
 MT
Sector Update: Health Care Stocks Higher Monday Afternoon
10-14
 MT
Vanda Pharmaceuticals Shares Rise; Cycle Pharmaceuticals' Buyout Offer Rejected Again
10-14
 MT
Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer
10-14
 RE
Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million.
10-13
 CI
Vanda Pharma Shares Fall 15% as FDA Denies Approval of Tradipitant NDA for Treating Gastroparesis Symptoms
09-19
 MT
Top Premarket Decliners
09-19
 MT
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
09-19
 CI
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q2 Revenue $50.5M, vs. Street Est of $47.9M
07-31
 MT
Vanda Pharmaceuticals Inc. Reinstates Financial Guidance for the Full Year 2024
07-31
 CI
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
07-31
 CI
Vanda Pharmaceuticals Says Federal Court Allows Patent Lawsuit Over Hetlioz
07-01
 MT
Future Pak withdraws offer to buy Vanda Pharmaceuticals
06-26
 RE
Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc., Butler Hall Capital LLC, Shareholder Capital LLC and others.
06-25
 CI
Vanda rejects Future Pak and Cycle Pharma's takeover offers
06-20
 RE
Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc..
06-18
 CI
Sector Update: Health Care Stocks Ease Late Afternoon
06-13
 MT
Sector Update: Health Care Stocks Softer Thursday Afternoon
06-13
 MT
Sector Update: Health Care
06-13
 MT
Vanda Pharmaceuticals Receives Revised Offer From Future Pak; Shares Rise
06-13
 MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VNDA Stock
  4. News Vanda Pharmaceuticals Inc.
  5. Highlights
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition